Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China

OBJECTIVE: The ASTRUM-007 trial (NCT03958890) demonstrated that serplulimab plus chemotherapy administered every 2-week significantly improved progression-free and overall survival in patients with previously untreated, programmed death-ligand 1 (PD-L1) positive advanced esophageal squamous-cell car...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shixian, Jiang, Nana, Dou, Lei, Li, Shunping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192749/
https://www.ncbi.nlm.nih.gov/pubmed/37215110
http://dx.doi.org/10.3389/fimmu.2023.1172242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192749/
https://www.ncbi.nlm.nih.gov/pubmed/37215110
http://dx.doi.org/10.3389/fimmu.2023.1172242

Ejemplares similares